An outbreak of severe infections among Australian infants caused by a novel recombinant strain of human parechovirus type 3

Human parechovirus types 1–16 (HPeV1–16) are positive strand RNA viruses in the family Picornaviridae . We investigated a 2015 outbreak of HPeV3 causing illness in infants in Victoria, Australia. Virus genome was extracted from clinical material and isolates and sequenced using a combination of next...

Full description

Saved in:
Bibliographic Details
Published in:Scientific reports Vol. 7; no. 1; p. 44423
Main Authors: Nelson, Tiffanie M., Vuillermin, Peter, Hodge, Jason, Druce, Julian, Williams, David T., Jasrotia, Rekha, Alexandersen, Soren
Format: Journal Article
Language:English
Published: London Nature Publishing Group UK 14-03-2017
Nature Publishing Group
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Human parechovirus types 1–16 (HPeV1–16) are positive strand RNA viruses in the family Picornaviridae . We investigated a 2015 outbreak of HPeV3 causing illness in infants in Victoria, Australia. Virus genome was extracted from clinical material and isolates and sequenced using a combination of next generation and Sanger sequencing. The HPeV3 outbreak genome was 98.7% similar to the HPeV3 Yamagata 2011 lineage for the region encoding the structural proteins up to nucleotide position 3115, but downstream of that the genome varied from known HPeV sequences with a similarity of 85% or less. Analysis indicated that recombination had occurred, may have involved multiple types of HPeV and that the recombination event/s occurred between March 2012 and November 2013. However the origin of the genome downstream of the recombination site is unknown. Overall, the capsid of this virus is highly conserved, but recombination provided a different non-structural protein coding region that may convey an evolutionary advantage. The indication that the capsid encoding region is highly conserved at the amino acid level may be helpful in directing energy towards the development of a preventive vaccine for expecting mothers or antibody treatment of young infants with severe disease.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2045-2322
2045-2322
DOI:10.1038/srep44423